Ovid Therapeutics ownership filing by Point72 group reports shared holdings of 1,903,943 common shares (including warrants) representing 1.3% of the outstanding stock. The statement, dated as of the close of business on March 31, 2026, attributes shared voting and dispositive power to Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen for the reported position.
The filing states the 1.3% figure is calculated on an aggregate base of 151,028,955 shares outstanding, which combines 131,874,634 shares reported as of March 16, 2026 and 19,154,321 shares issued in a private placement on March 17, 2026, and assumes exercise of the reported warrants.
Positive
None.
Negative
None.
Insights
Point72 reports a modest, shared 1.3% position in Ovid, including warrant exposure.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen are reported with shared voting and dispositive power over 1,903,943 shares, which the filing ties to an assumed exercise of 583,333 warrants. The position is presented as of the close of business on March 31, 2026.
Cash‑flow treatment and planned dispositions are not stated in the excerpt; subsequent filings would disclose any sales. The filing follows Schedule 13G/A reporting conventions and frames the percentage on an aggregate 151,028,955 shares outstanding base.
Key Figures
Reported shares beneficially owned:1,903,943 sharesWarrants issuable:583,333 sharesPercent of class:1.3%+2 more
5 metrics
Reported shares beneficially owned1,903,943 sharesshared power reported as of March 31, 2026
Warrants issuable583,333 sharesincluded in the reported position as issuable upon exercise
Percent of class1.3%calculated on 151,028,955 shares outstanding
Shares outstanding base151,028,955 sharessum of 131,874,634 (as of March 16, 2026) and 19,154,321 issued March 17, 2026
Shared voting/dispositive power1,903,943 sharesreported shared voting and dispositive power for Point72 and Steven A. Cohen
Key Terms
shared dispositive power, warrants issuable upon exercise, Schedule 13G/A
3 terms
shared dispositive powerregulatory
"Includes entries showing "Shared Dispositive Power 1,903,943.00""
warrants issuable upon exercisefinancial
"Includes 583,333 shares of Common Stock issuable upon exercise of warrants"
Schedule 13G/Aregulatory
"Form type listed as SCHEDULE 13G/A on the cover and Item 2 descriptions"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Point72 reports shared beneficial ownership of 1,903,943 shares, representing 1.3% of the class. The filing includes 583,333 shares issuable upon exercise of warrants and is measured on a 151,028,955 share base.
How was the 1.3% ownership percentage calculated for OVID?
The percentage is calculated on an aggregate of 151,028,955 shares outstanding, combining 131,874,634 shares as of March 16, 2026 and 19,154,321 shares from a March 17, 2026 private placement, and assumes exercise of reported warrants.
Which entities are named as reporting persons on the Schedule 13G/A?
The filing names Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons, with shared voting and dispositive power reported for the position as of March 31, 2026.
Does the filing show who will receive proceeds if shares are sold?
The excerpt does not state the cash‑flow treatment for future sales. It only reports shared voting/dispositive power and beneficial ownership as of March 31, 2026; proceeds recipients are not disclosed in the provided text.
Are warrants included in the reported OVID position?
Yes. The filing expressly states inclusion of 583,333 shares issuable upon exercise of warrants in the reported 1,903,943 share position and in the percentage calculation.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Ovid Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
690469101
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,903,943.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,903,943.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,903,943.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Includes 583,333 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,903,943.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,903,943.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,903,943.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Includes 583,333 shares of Common Stock issuable upon exercise of warrants.
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,903,943.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,903,943.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,903,943.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Includes 583,333 shares of Common Stock issuable upon exercise of warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Ovid Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
441 Ninth Avenue, 14th Floor, New York, NY 10001
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Ovid Therapeutics Inc. ( the "Issuer") held by (and shares of Common Stock underlying the warrants held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by (and shares of Common Stock underlying the warrants held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
690469101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 151,028,955 shares of Common Stock outstanding, which is the sum of (i) 131,874,634 shares of Common Stock outstanding as of March 16, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 18, 2026, and (ii) 19,154,321 shares of Common Stock issued in the private placement entered into on March 17, 2026, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 18, 2026, and assumes the exercise of the warrants reported herein.
(b)
Percent of class:
1.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
